Atlas Trials

A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS

Clinical trial NCT04044209 · WITHDRAWN

Trial details

NCT number
NCT04044209
Sponsor
Yale University
Status
WITHDRAWN
Phase
Phase 2
Study type
INTERVENTIONAL
Myelodysplastic SyndromesAcute Myeloid Leukemia
Start date
2020-02-12
Primary completion
2021-09-01
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.